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Abstract
Background: Little data exist on how opioid doses vary with the length of exposure among chronic opioid users.
Methods: To characterize the change in the dosage of opioids over time, a retrospective cohort study using the 
PharMetrics database for the years 1999 through 2008 was conducted. Individuals exposed to opioids in 2000 who had 
2 opioid dispensings at least 6 months apart and were opioid naive (did not receive any opioid 6 month before their 
exposure in 2000) were included. The date of the first dispensing in 2000 was defined as the index date and the 
dispensing had to be for a strong and full agonist opioid. All opioid doses were converted to oral morphine equivalent 
doses. Exposure was classified as continuous or intermittent. Mean, median, interquartile range, and 95th percentile of 
opioid dose over 6-month periods, as well as the percentage of subjects who ever received a high or very high opioid 
dose, were calculated.
Results: Among the 48,986 subjects, the mean age was 44.5 years and 54.5% were women. Intermittent exposure was 
observed in 99% of subjects; continuous exposure was observed in 1% of subjects. The mean duration of exposure for 
the subjects who were continuously exposed to opioids was 477 days. In subjects with no cancer diagnosis who were 
continuously exposed to opioids, the mean, 25th, 50th, and 75th percentile of dose was stable during the first 2 years of 
use, but the 95th percentile increased. Seven percent of them were exposed to doses of 180 mg or more of morphine at 
some point.
Conclusions: Dose escalation is uncommon in subjects with intermittent exposure to opioids. For subjects with 
continuous exposure to opioids who have cancer, doses rise substantially with time. For those without cancer, doses 
remain relatively stable for the first 2 years of use, but subsequently increase. Seven percent of subjects with no cancer 
diagnosis will be exposed to daily doses of 180 mg or more of morphine equivalent at some point.
Background
Opioids are increasingly used for the treatment of
chronic malignant and nonmalignant pain [1,2] and sys-
tematic reviews of randomized controlled trials have con-
firmed their short-term efficacy for the treatment of
neuropathic pain, back pain, ostearthritis, cancer pain,
and fibromyalgia [3-8].
However, in some cases with chronic use, the dose of
opioids may increase because of disease progression, the
development of tolerance and/or the development of a
state of abnormal high pain sensitivity (hypersensitivity)
that opioids themselves may induce. Hypersensitivity is a
poorly understood phenomenon thought to result from
opioid-induced neuroplastic changes in the peripheral
and central nervous systems that lead to sensitization of
pronociceptive pathways [1,9].
Little data exist to support the long-term efficacy of
opioids or to describe the relation between opioid dose
and the length of exposure among chronic opioid users
[10]. Although randomized controlled trials have evalu-
ated opioids for the treatment of chronic pain, most of
these trials have limited follow-up periods (around 16
weeks) [3-5] and in the trials with longer follow-up peri-
ods, the lack of generalizability of the findings has been
identified as a serious shortcoming [4].
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Claims databases provide an opportunity to close this
gap in knowledge. These databases are a collection of
health insurance claims that are maintained largely for
billing and administrative purposes. Nevertheless, they
permit the evaluation of not only a diverse population,
but also a large number of subjects followed over a rela-
tively long period of time in a real-world setting [11].
Health care databases have been used extensively for
pharmacoepidemiologic research in many therapeutic
areas including pain [12-14] to describe health care utili-
zation, patterns of care, disease prevalence, drug and dis-
ease outcomes, and cost of care. There are, however,
limitations to the use of health care databases for phar-
macoepidemiologic research: they are observational,
which limits inferences about treatment efficacy relative
to studies that include random allocation to treatment
[11]; they may not include information on important con-
founding factors (eg, smoking), and they may include
diagnoses that are provisional or whose selection may be
affected by reimbursement policies. The advantages to
the use of these databases are the availability of system-
atic and accurate information on prescribed medications
[11], their ability to follow patients for many years, and
the fact that they reflect clinical practice in a population
that is not subject to the same selection biases as might
apply to those who volunteered for inclusion in a study. In
fact, health care databases often are used to explain dif-
ferences in findings between trial data and clinical prac-
tice [15].
We sought to characterize the dose of opioids in both
cancer and noncancer patients intermittently and chroni-
cally exposed to opioids using PharMetrics Patient-Cen-
tric database. PharMetrics is the largest health care
claims database in the United States and is representative
of the commercially insured population. Data for more
than 61 million individuals from more than 98 health
plans across the United States are available and include
information on all hospitalizations, emergency care,
office visits, and drug dispensing covered by insurance.
Methods
To characterize the change in the dose of opioids over
time, a retrospective cohort study using the PharMetrics
Patient-Centric database for the years 1999 through 2008
was conducted. Access to the PharMetrics database
requires a license agreement and the data are provided
de-identified. Tabulations from these data do not require
ethics approval.
Inclusion and exclusion criteria
Opioid-naive individuals exposed to opioids in 2000 who
had 2 strong opioid dispensings at least 6 months apart
(to focus on subjects with long-term opioid exposure),
regardless of the duration of the prescription, were
included. Opioid-naive individuals were defined as sub-
jects who did not receive any type of opioid for at least 6
months before their first opioid dispensing in 2000.
The date of the first dispensing of a strong opioid pre-
scription in 2000 was defined as the index date. The dis-
pensing at the index date had to be for a strong and full
agonist opioid (e.g., morphine, hydromorphone), Table 1.
Oral, rectal, transdermal, subcutaneous, intramuscular or
intravenous routes of administration and all forms of pre-
sentation (immediate release or controlled release) were
included. A subject remained in the cohort even if after
receiving a strong opioid at the index date, he or she sub-
sequently received a weak, agonist antagonist, or partial
agonist opioid. All opioid doses were converted into oral
morphine equivalent doses.
Patients who were receiving opioids for the treatment
of opioid addiction were excluded. To determine pres-
ence of addiction before the index date, the International
Statistical Classification of Diseases and Related Health
Problems, ninth edition (ICD-9) diagnostic codes for
drug dependence or drug abuse were used.
Pattern of exposure
Exposure was classified as either continuous or intermit-
tent. A subject was defined as "continuously exposed" if
there were no time gaps between the dispensing of opi-
oids, and "intermittently exposed" if there was a time gap
between the dispensing of opioids. A gap was considered
to occur when the number of days between 2 dispensings
was more than 4 times the number of days supplied by
the previous dispensing. Four times the days supplied was
Table 1: Strong opioids dispensed at index date
Opioid medication Percentage
Fentanyl 0.2
Hydrocodone 78.8
Hydromorphone 0.2
Meperidine 1.7
Methadone 0.004
Morphine 0.2
Oxycodone 18.7
Oxymorphone 0.002
*Percentages may not add up to 100% because of rounding.Cepeda et al. BMC Palliative Care 2010, 9:14
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used to take into account that some patients may have
taken the medication less often than prescribed.
Daily dose and dose over time
Daily dose was calculated from the quantity dispensed
and the days supplied. Daily doses were re-expressed as
oral morphine equivalents using the conversion factors
shown in Table 2.
To determine the behavior of opioid dose over time,
mean, median dosage, interquartile range and 95th per-
centile of opioid dose over 6-month periods from the
index date were calculated. Opioid doses are reported
separately for subjects with intermittent or continuous
exposures and, for subjects with continuous exposure, by
the presence or absence of a cancer diagnosis.
To address the possibility that aggregate dose changes
at the cohort level might be affected by selective loss of
the subjects with the highest or lowest doses, in each 6-
month period, the dose of opioids for subjects who
remained in the cohort during all or part of the next 6-
m o n t h  pe r i od  w e r e  e x a m i n e d  s e p a r a t e l y  f r o m  s u b j e c ts
who, for any reason, did not continue to the next 6-
month period.
The database does not explicitly link medication dis-
pensings to their indications. To assess the likely indica-
tions for the opioids that were dispensed, ICD-9 pain-
related diagnostic codes were grouped into cancer, mus-
culoskeletal, migraine, neuropathic, and other. Because
many opioid dispensings did not have an ICD-9 pain-
related diagnosis that was close in time, no time limita-
tion was placed on these pain diagnoses.
The percentage of subjects who ever received a high or
very high opioid dose was also calculated. Morphine
equivalents of 180 mg/day or more were considered as
the high dose category, and morphine equivalents of 300
mg/day or more were considered as the very high dose
category [1,16]. In addition, the percentage of subjects
who ever received morphine equivalents of 100 mg/day
or more was also calculated as such doses have been asso-
ciated with an increase risk of overdose [17].
The analyses were performed in STATA IC version
10.1.
Results
A total of 57,345 subjects were exposed to opioids start-
ing in 2000 for at least 6 months and met the inclusion
criteria. Of these, 8,362 (14%) subjects were excluded
because of missing data on the quantity dispensed or the
days supplied, leaving 48,986 subjects whose dosage pat-
terns were examined in the present study. Among these
subjects, the mean age was 44.5 years and 54.5% were
women. Subjects were diagnosed with various possible
types of pain (some subjects were diagnosed with more
than one type), including musculoskeletal, 77.6%; neuro-
pathic, 35.3%; migraine, 27.8%; and cancer, 24.2%.
At the index date, the most frequently dispensed opioid
was hydrocodone (78.8% of subjects), followed by oxy-
codone (18.7% of subjects) and meperidine (1.7% of sub-
jects). Fentanyl, hydromorphone, methadone, morphine,
and oxymorphone together accounted for the remaining
0.8% of dispensing at the index date (Table 1).
Pattern of exposure: Intermittent and continuous
Intermittent exposure was observed among 48,367 (99%)
of subjects; continuous exposure was observed among
619 (1%) of subjects. The median number of opioid dis-
pensings was 5 for subjects with intermittent exposure
Table 2: Morphine equivalent conversion factors
Opioid drug Oral morphine equivalent dose
Buprenorphine Multiplied by 60
Butorphanol Multiplied by 7
Codeine Divided by 12
Dihydrocodeine Divided by 10
Fentanyl (patch) Multiplied by 150
Hydrocodone Multiplied by 1.5
Hydromorphone (oral) Multiplied by 5
Hydromorphone 
(parenteral)
Multiplied by 10
Levorphanol Multiplied by 6
Meperidine Divided by 12
Methadone Multiplied by 10
Morphine (parenteral) Multiplied by 2
Oxycodone Multiplied by 1.5
Oxymorphone Multiplied by 10
Pentazocine Divided by 4
Propoxyphene Divided by 24
Tramadol Divided by 5Cepeda et al. BMC Palliative Care 2010, 9:14
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(range, 2-319 dispensings) and 13 for subjects with con-
tinuous exposure (range, 2-275 dispensings). The mean
duration of exposure in the subjects continuously
exposed to opioids was 477 days (range, 6 months to 8
years).
The median daily dose of morphine equivalent in the
subjects with intermittent exposure remained stable over
time, at approximately the equivalent of 50 mg oral mor-
phine per day. The mean (approximately 60 mg), twenty-
fifth percentile (approximately 30 mg), seventy-fifth per-
centile (approximately 60 mg) and ninety-fifth percentile
(approximately 120 mg) doses were also stable over time
(Table 3).
Six hundred and nineteen subjects were continuously
exposed to opioids for at least 6 months, and 6 years after
the index day, only 9 subjects were continuously exposed
to opioids. The daily morphine equivalent dose in sub-
jects with continuous exposure and no cancer diagnosis
remained stable for the first two years, as measured by
mean (approximately 70 mg), median (approximately 50
mg), twenty-fifth (approximately 30 mg) or seventy-fifth
percentiles (approximately 75 mg), but the 95th percentile
dose rose from 143 mg to 185 mg. After the second year
of continuous exposure, although the median dose
remained stable, the mean, seventy-fifth percentile and
Table 3: Morphine equivalent daily dose by time in subjects with intermittent exposure
Years Number of subjects Mean ± SD Median Min Max P25 P75 P95
Half year 48367 62.48 ± 76.43 50.00 0.25 2700.00 37.50 69.17 112.50
> 6 months to 1 year 22494 57.61 ± 85.68 45.00 0.33 6666.67 31.50 65.16 112.50
> 1 to 1.5 years 19130 56.07 ± 69.1 45.00 0.50 2250.00 30.00 64.11 112.50
> 1.5 to 2 years 15553 56.97 ± 73.8 45.00 0.50 2025.00 30.00 65.00 112.50
> 2 to 2.5 years 11588 58.45 ± 69.05 46.15 0.67 1920.00 30.00 67.50 113.44
> 2.5 to 3 years 8119 60.73 ± 82.99 46.88 0.67 1920.00 30.94 67.50 120.00
> 3 to 3. 5 years 5824 58.23 ± 81.27 45.00 1.56 2660.63 30.00 64.29 112.50
> 3. 5 to 4 years 4677 55.71 ± 75.7 45.00 2.50 1808.04 30.00 60.00 112.50
> 4 to 4.5 years 4619 58.57 ± 87.44 45.00 2.50 2025.00 30.00 60.00 120.00
> 4.5 to 5 years 4111 59.42 ± 100.09 45.00 2.50 2700.00 30.00 60.00 112.50
> 5 to 5.5 years 3418 58.56 ± 96.34 45.00 2.50 3535.12 30.00 60.00 120.00
> 5.5 to 6 years 3301 62.96 ± 113.2 45.00 2.50 2890.19 30.00 61.25 120.00
> 6 to 6.5 years 3225 61.66 ± 109.87 45.00 2.45 3368.28 30.00 62.00 120.00
> 6.5 to 7 years 3031 61.81 ± 101.48 45.00 2.50 2239.86 30.00 60.99 114.28
> 7 to 7.5 years 1837 64.44 ± 116.78 45.00 3.75 2695.92 30.00 60.00 128.57
> 7.5 to 8 years 714 62.71 ± 103.76 45.00 4.17 1350.00 30.00 56.25 146.93
> 8 years 179 72.52 ± 124.42 46.32 6.94 937.50 28.75 60.00 300.00
SD, standard deviation; P25, 25th percentile; P75; 75th percentile; P95; 95th percentileCepeda et al. BMC Palliative Care 2010, 9:14
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ninety-fifth percentile doses rose gradually. After the
f o u rt h  y e a r  o f  c o n t i n u o us  e x po s u r e  t h e  m ed ia n  o p i o i d
dose increased as well, though it should be noted that the
number of subjects was small. The daily morphine equiv-
alent dose in subjects with continuous e xposure and a
cancer diagnosis increased earlier than in subjects with-
out cancer diagnosis (Tables 4 and 5).
The opioid dose among subjects whose exposure ended
in a given 6-month time period was similar to the opioid
dose among subjects who remained exposed in the next
6-month time period (Table 6).
Exposure to high doses of opioids
In subjects who were intermittently exposed to opioids
exposure to high doses (180 mg or more of oral morphine
equivalent) occurred at some point in 2,095 (4%) subjects
and 1,257 (2.6%) were exposed to very high doses (300 mg
or more of oral morphine equivalent).
In subjects who were continuously exposed to opioids,
7.6% were exposed to high doses of opioids and 2.9% were
exposed to very high doses of opioids at some point. Ten
percent of subjects who were continuously exposed to
opioids with a cancer diagnosis were exposed to high
doses of opioids compared with 7% of subjects who were
Table 4: Morphine equivalent daily dose by time in subjects with continuous exposure without cancer diagnosis
Years Number of subjects Mean ± SD Median Min Max P25 P75 P95
Half year 442 62.53 ± 69.88 45.04 7.5 802.13 30.54 67.5 142.5
> 6 months to 1 year 305 62.11 ± 65.73 45 7.5 486.86 30 64.29 170
> 1 to 1.5 years 173 66.37 ± 64.39 46.61 7.5 480 30 73.5 197.14
> 1.5 to 2 years 107 64.6 ± 62.1 45.8 7.5 342.86 30 64.29 184.85
> 2 to 2.5 years 67 71.96 ± 70.86 50.63 8.33 360 30 82.12 183.33
> 2.5 to 3 years 29 88.2 ± 91.12 60 8.33 420 39.99 95.45 330
> 3 to 3. 5 years 19 91.05 ± 115.16 53.09 8.33 480 30 90.91 480
> 3. 5 to 4 years 14 68.13 ± 53.39 52.5 15 187.5 24.64 107.76 187.5
> 4 to 4.5 years 12 90.38 ± 79.83 52.5 15 244.55 30 169 244.55
> 4.5 to 5 years 9 80.99 ± 61.23 60 22.5 183 45 95.98 183
> 5 to 5.5 years 6 111.56 ± 72.04 117.18 22.5 187.5 45 180 187.5
> 5.5 to 6 years 6 122.59 ± 89.37 120.27 22.5 240 45 187.5 240
> 6 to 6.5 years 5 122.88 ± 105.75 75 22.5 255 45 216.92 255
> 6.5 to 7 years 5 133.5 ± 132.31 60 22.5 330 45 210 330
> 7 to 7.5 years 2 123.41 ± 110.89 123.41 45 201.82 45 201.82 201.82
> 7.5 to 8 years 2 127.5 ± 116.67 127.5 45 210 45 210 210
>  8  y e a r s 1 4 5  ±  . 4 5 4 54 5 4 54 54 5
SD, standard deviation; P25, 25th percentile; P75; 75th percentile; P95; 95th percentileCepeda et al. BMC Palliative Care 2010, 9:14
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continuously exposed to opioids without a cancer diagno-
sis.
In subjects intermittently exposed to opioids, 18.7%
reached doses of 100 mg or more of oral morphine equiv-
alent. In subjects continuously exposed to opioids, 19.9%
reached doses of 100 mg or more of oral morphine equiv-
alent.
Discussion
The present study reports the patterns of opioid use in a
large diverse population across the United States over a
substantial time period. Such data are difficult to obtain
in traditional clinical studies, but are readily available in
pharmacoepidemiologic database studies.
The study showed that intermittent exposure to opioids
is a common phenomenon, a finding that has been
described previously [18], and that in subjects with inter-
mittent exposure, the dose of opioids remains stable over
time. This group potentially includes subjects with sub-
acute pain, pain exacerbations and chronic pain.
The initial median daily oral morphine equivalent dose
was approximately 50 mg. Such doses aligned with those
reported in studies performed in chronic pain clinics [19]
and in the general population [18]. In the latter study, Von
Korff et al described opioid use in noncancer patients in 2
US health plans.
In subjects with no cancer diagnosis and continuous
exposure to opioids, the 95th percentile dose rose early,
Table 5: Morphine equivalent daily dose by time in subjects with continuous exposure with cancer diagnosis
Years Number of subjects Mean ± SD Median Min Max P25 P75 P95
Half year 177 65.29 ± 67.61 50.00 7.50 699.57 33.88 77.73 140.63
> 6 months to 1 year 148 86.63 ± 156.56 55.44 7.50 1702.50 30.00 89.10 240.00
> 1 to 1.5 years 79 71.96 ± 86.73 51.46 10.56 560.00 26.25 79.29 294.49
> 1.5 to 2 years 39 90.96 ± 92.61 60.00 15.00 431.88 30.00 98.12 347.94
> 2 to 2.5 years 19 99.55 ± 87.31 75.00 15.00 300.00 37.50 120.00 300.00
> 2.5 to 3 years 9 116.79 ± 95.72 105.00 15.00 318.12 45.00 139.74 318.12
> 3 to 3. 5 years 5 121.9 ± 130.19 45.00 15.00 298.74 27.50 223.27 298.74
> 3. 5 to 4 years 5 115.78 ± 125.49 45.00 15.00 295.71 23.82 199.38 295.71
> 4 to 4.5 years 5 151.37 ± 182.88 45.00 15.00 436.67 26.25 233.96 436.67
> 4.5 to 5 years 4 304.47 ± 422.07 141.43 15.00 920.00 30.00 578.93 920.00
> 5 to 5.5 years 3 394.28 ± 457.61 240.00 33.75 909.09 33.75 909.09 909.09
> 5.5 to 6 years 3 400.01 ± 471.87 233.78 33.75 932.50 33.75 932.50 932.50
> 6 to 6.5 years 3 315.39 ± 321.23 240.00 38.57 667.61 38.57 667.61 667.61
> 6.5 to 7 years 2 187.59 ± 209.35 187.59 39.55 335.62 39.55 335.62 335.62
> 7 to 7.5 years 1 381.73 ± . 381.73 381.73 381.73 381.73 381.73 381.73
> 7.5 to 8 years 0 - - - - - - -
>  8  y e a r s 0 - -- ----
SD, standard deviation; P25, 25th percentile; P75; 75th percentile; P95; 95th percentileCepeda et al. BMC Palliative Care 2010, 9:14
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but the mean, 25th, 50th, and 75th  percentile doses
remained stable for the first 2 years of use then increased.
However, over the full eight year course of the study the
median dose of 45 mg increased to 130 mg and the 95th
percentile dose increased from 142 mg to 210 mg. Seven
percent of subjects with no cancer diagnosis received at
some point in time high doses of opioids.
The results of the present study are similar to the study
by Bercovitch et al in patients receiving palliative care for
terminal illnesses. These authors found that only a small
percentage of subjects (approximately 9%) required doses
of morphine equivalent to 300 mg or more [16]. The
study by Sullivan et al, although not directly assessing the
variation of opioid dose over time, corroborates our find-
ings [2]. In that study, opioid use was characterized in
commercially insured and publicly insured populations
over a 6-year period. The study found that the cumulative
yearly opioid dose increase was due to increases in the
number of days supplied rather than the dose per day
supplied [2].
Table 6: Morphine equivalent median daily doses in subjects continuously exposed to opioids by time and by permanence 
in the cohort
Time period Number of subjects 
who did not continue
Median dose in 
subjects who did not 
continue
Number of subjects 
who continued 
exposure
Median dose in 
subjects who 
continued exposure
Half year 166 56.25 453 45.0
> 6 months to 1 year 200 48.21 253 44.4
> 1 to 1.5 years 107 51.45 145 45.0
> 1.5 to 2 years 60 46.07 86 49.75
> 2 to 2.5 years 48 45.67 38 60.0
> 2.5 to 3 years 14 75.5 24 54.06
> 3 to 3. 5 years 5 60 19 52.2
> 3. 5 to 4 years 2 47.14 17 45.0
> 4 to 4.5 years 4 30.52 13 60.0
> 4.5 to 5 years 4 37.5 9 96.0
> 5 to 5.5 years 0 -- 9 156.4
> 5.5 to 6 years 1 240.0 8 120.0
> 6 to 6.5 years 1 240.0 7 75.0
> 6.5 to 7 years 4 49.8 3 210.0
> 7 to 7.5 years 1 381.7 2 123.4
> 7.5 to 8 years 1 210.0 1 45.0
Median dose 56.25 45.0Cepeda et al. BMC Palliative Care 2010, 9:14
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The very large number of subjects exposed to opioids
intermittently permits us to characterize with confidence
the dose of opioids over time. On the other hand, only a
small number of subjects were continuously exposed to
opioids for more than 4 years. Therefore, extrapolating
the findings of the study beyond this time period is not
recommended.
Dose escalation is considered one of the major factors
that could curtail the effectiveness of opioids [1,10]. The
findings of this study show that dose escalation among
commercially insured patients who are prescribed opi-
oids continuously occurred in seven percent of subjects.
For most subjects with continuous exposure, dose escala-
tion was seen only after the first 2 years of use. A study in
a different population, subjects with back injuries at risk
for long term disability continuously exposed to opioids
for a year, found a more rapid dose escalation --thirty
nine percent of subjects moved to a higher dose category
at the last quarter of follow up [20].
Exposure to opioids could lead to serious adverse
events. A recent study that assessed the risk of overdose
in subjects who had continuously received opioids for
chronic non-cancer pain for at least three months found
overdoses among 0.5% of subjects (1.5 events/1,000 per-
son years of follow-up), and observed that subjects
receiving 100 mg or more of morphine had a nine-fold
increase in overdose risk [17]. In the present study
approximately twenty percent of the subjects received
s u c h  d o s e s ,  a t  s o m e  t i m e  d u r i n g  t r e a t m e n t .  P a t i e n t s
receiving these doses need close supervision. Future
research should attempt to better define the patient
groups in which prescription of opioids for non-cancer
pain is safe, and those in which it is not.
Among the limitations of the present study, are: the
PharMetrics Patient-Centric database reflects the com-
mercially insured population and, therefore, overrepre-
sents the healthy population which is able to work and
underrepresents individuals 65 years or older and dis-
abled and low income populations which are insured
through Medicare or Medicaid programs. These limita-
tions could affect the generalizability of the study find-
ings. Attrition of subjects because of loss of health
insurance may also affect a study like the present one,
that is based on claims data, but some reassurance about
this possible source of bias is provided by the finding
doses in the preceding six months were similar for sub-
jects who left the cohort and those who remained in it. In
addition, the claims database reflects only those dispens-
ings that were submitted for reimbursement in the outpa-
tient setting. It is not able to identify medications that a
patient may have obtained outside the health care benefit
system. However, the PharMetrics Patient-Centric data-
base captures data from all retail and mail-order dispens-
ing regardless of which health care provider in the plan
issues the prescription.
Pain intensity or pain relief information is absent in
claims databases. Therefore, it is unknown whether sub-
jects stopped treatment with opioids because of disease
improvement, the lack of efficacy, or the lack of tolerabil-
ity. Systematic reviews have found that up to one third of
patients in clinical trials withdraw because of opioid
adverse events and up to 18% of patients withdraw
because of inadequate pain relief [3,5].
The inability to link with certainty the opioid dispens-
ings directly to the diagnoses that they were intended to
address, and the fact that PharMetrics uses the ICD-9
system to code the medical diagnosis, precluded the use
of a pain taxonomy based on the pain mechanism. Thus,
no attempts were made to compare opioid dose across
pain categories, with the exception of the presence of
cancer diagnosis.
The pattern of dose escalation observed in this study
could be a reflection of the success of the adequate
patient selection and careful evaluation by health care
providers when prescribing opioids. Consequently, physi-
cians and other health care providers should continue fol-
lowing the principles of good medical practice, and
develop treatment plans tailored to the individual and the
presenting problem when prescribing opioids, as recom-
mended by many pain organizations such as the Ameri-
can Academy of Pain Medicine and the American Pain
Society [21].
Conclusions
Dose escalation is uncommon in subjects with intermit-
tent exposure to opioids.
For subjects with continuous exposure to opioids who
have cancer, doses rise substantially with time. For those
without cancer, doses remain relatively stable for the first
2 years of use, but subsequently increase. Seven percent
of subjects with no cancer diagnosis will be exposed to
daily doses of 180 mg or more of morphine equivalent at
some point
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